HighTower Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$269K Buy
3,419
+9
+0.3% +$625 ﹤0.01% 3301
2026
Q2
$215K Sell
3,410
-20
-0.6% -$1.28K ﹤0.01% 3488
2026
Q1
$241K Sell
3,430
-194
-5% -$13.6K ﹤0.01% 3348
2025
Q4
$297K Sell
3,624
-65
-2% -$4.85K ﹤0.01% 3056
2025
Q3
$219K Buy
+3,689
New +$182K ﹤0.01% 3296
2025
Q1
– Sell
-3,734
Closed -$207K – 4043
2024
Q4
$207K Buy
+3,734
New +$170K ﹤0.01% 3175

Other funds holding TARS

HighTower Advisors's TARS Position: Q3 2026 in Review

HighTower Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 0.26% in Q3 2026, buying an estimated $625 and bringing the position to 3,419 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

HighTower Advisors first reported a position in TARS in Q4 2024 and has held it in 6 quarters since. The position peaked at $297K in Q4 2025. 200 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • HighTower Advisors held 3,419 shares of Tarsus Pharmaceuticals worth $269K as of Q3 2026.
  • HighTower Advisors bought 9 Tarsus Pharmaceuticals shares in Q3 2026, an estimated $625.
  • Tarsus Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3301 holding.
  • HighTower Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • HighTower Advisors's Tarsus Pharmaceuticals position peaked at $297K in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.